Shanghai Haohai Biological Technology Co., Ltd. (“Haohai Biotec”) submitted a Next Day Disclosure Return on 13 May 2026 detailing recent share repurchase activity on the Hong Kong Stock Exchange (HKEX).

Key share capital snapshot • Total issued ordinary shares (excluding treasury shares) remain unchanged at 226.13 million, comprising 190.20 million A-shares (unlisted in Hong Kong) and 35.93 million H-shares. • Treasury stock stands at 3.85 million A-shares; no H-shares are held in treasury.

H-share repurchase programme • Between 23 March and 13 May 2026, Haohai Biotec bought back 1.11 million H-shares that are pending cancellation. • The cumulative buy-backs equal 3.10 % of the H-share float and roughly 0.49 % of total ordinary shares. • Based on disclosed volume-weighted prices, the company spent approximately HK$24.69 million (about 24.69 million) at an average HK$22.19 per share.

Latest transaction (13 May 2026) • Volume: 31,500 H-shares • Price range: HK$22.08–HK$22.46 • Average price: HK$22.33 • Consideration: HK$0.70 million

Repurchase mandate utilisation • Board mandate granted on 10 June 2025 permits the repurchase of up to 3.91 million shares. • Cumulative repurchases under this mandate total 3.71 million shares, representing 94.86 % of the authorised quota. • In line with listing rules, Haohai Biotec is restricted from issuing new shares until 12 June 2026.

No immediate impact on share count Although the repurchased H-shares have not yet been cancelled, the company’s issued share capital remains unchanged as of the disclosure date. Cancellation will reduce the outstanding H-shares once processed, but this has not yet been reflected in the share register.